drug_type
RELEVANT_DRUG
intervention_type
cellular vaccine (autologous dendritic cell therapy)
drug_description
Autologous cellular immunotherapy in which patient-derived dendritic cells are pulsed with tumor-specific neoantigen peptides to present via HLA class I/II and prime/expand neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells.
nci_thesaurus_concept_id
C148188
nci_thesaurus_definition
An autologous dendritic cell (DC) vaccine composed of DCs loaded with multiple distinct neoantigens, with potential immunomodulating and antineoplastic activities. Upon administration, the neo-multiple tumor-associated antigens (TAA)-loaded DC vaccine may stimulate a cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing these neoantigens.
drug_mesh_term
Cancer Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Autologous dendritic cells are loaded ex vivo with patient-specific tumor neoantigen peptides and, upon reinfusion, present these antigens via HLA class I and II to prime and expand neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, driving tumor-specific immune responses and killing of neoantigen-expressing cancer cells.
drug_name
Neoantigen-loaded dendritic cell vaccine
nct_id_drug_ref
NCT06752057